MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells
暂无分享,去创建一个
Tomoko Tadokoro | A. Morishita | S. Fujihara | H. Iwama | Koji Fujita | K. Oura | H. Kobara | Taiga Chiyo | Tsutomu Masaki | Megumi Okamura | Hiroki Yamana | Eri Samukawa | Yoshimi Yamana
[1] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[2] W. Blalock,et al. MiRNA-210: A Current Overview. , 2017, Anticancer research.
[3] T. Masaki,et al. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKa/mTOR pathway in vitro and in vivo , 2016, Oncotarget.
[4] Yang Yang,et al. MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1. , 2017, American journal of cancer research.
[5] S. Honda,et al. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T‐cell leukemia cells , 2016, FEBS open bio.
[6] J. Kinoshita,et al. The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer. , 2014, Cancer letters.
[7] J. Gröne,et al. Antiproliferative and apoptotic effects of telmisartan in human colon cancer cells , 2014, Oncology letters.
[8] I. da Silva,et al. Genetic Association Study of Angiotensin II Receptor Types 1 (A168G) and 2 (T1247G and A5235G) Polymorphisms in Breast Carcinoma among Brazilian Women , 2014, Breast Care.
[9] T. Masaki,et al. Targeting receptor tyrosine kinases in gastric cancer. , 2014, World journal of gastroenterology.
[10] H. Narahara,et al. Telmisartan Induces Growth Inhibition, DNA Double-Strand Breaks and Apoptosis in Human Endometrial Cancer Cells , 2014, PloS one.
[11] J. Holmes,et al. Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. , 2014, Journal of the National Cancer Institute.
[12] Yan-bin Zhao,et al. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. , 2013, Cancer letters.
[13] Yang Zhao,et al. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. , 2012, Oncology reports.
[14] K. Bhaskaran,et al. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database , 2012, BMJ : British Medical Journal.
[15] Robert L. Sutherland,et al. Cyclin D as a therapeutic target in cancer , 2011, Nature Reviews Cancer.
[16] H. Kitagawa,et al. Angiotensin II induces tumor progression and fibrosis in intrahepatic cholangiocarcinoma through an interaction with hepatic stellate cells. , 2010, International journal of oncology.
[17] D. Rowland,et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. , 2010, The Lancet. Oncology.
[18] Quynh-Thu Le,et al. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. , 2010, Translational oncology.
[19] M. Moore,et al. Advanced pancreatic carcinoma: current treatment and future challenges , 2010, Nature Reviews Clinical Oncology.
[20] B. Gudjonsson. Pancreatic cancer: survival, errors and evidence , 2009, European journal of gastroenterology & hepatology.
[21] J. Kinoshita,et al. Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. , 2009, International journal of oncology.
[22] Y. Kawahito,et al. Telmisartan as a peroxisome proliferator-activated receptor-γ ligand is a new target in the treatment of human renal cell carcinoma. , 2009, Molecular medicine reports.
[23] G. Wakabayashi,et al. Angiotensin II and epidermal growth factor receptor cross‐talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.
[24] Y. Matsuda. Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. , 2008, World journal of gastroenterology.
[25] Y. Kawahito,et al. Telmisartan is a potent target for prevention and treatment in human prostate cancer. , 2008, Oncology reports.
[26] M. Saif,et al. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. , 2007, JOP : Journal of the pancreas.
[27] J. Herman,et al. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1 , 2006, Oncogene.
[28] R. Schmid,et al. Pancreatic cancer: basic and clinical aspects. , 2005, Gastroenterology.
[29] Hidetaka Mochizuki,et al. The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness: Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2004, Pancreas.
[30] Mitchell A. Avery,et al. Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity , 2004, Hypertension.
[31] Yoshiaki Miyauchi,et al. Cyclins and cyclin‐dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis , 2003, Hepatology.
[32] A. Miyajima,et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. , 2002, Cancer research.
[33] Y. Sakamoto,et al. Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma. , 2001, Oncology reports.